A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.

被引：4

作者：

Ansell, Stephen M. ^{[1
]}

Tang, Hui

Kurtin, Paul

Koenig, Patricia

Inwards, David J. ^{[1
]}

Shah, Keith ^{[2
]}

Witzig, Thomas E. ^{[1
]}

机构：

[1] Mayo Clin, Coll Med, Rochester, MN USA

[2] Dayton Oncol Hematol Consultants, Dayton, OH USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

10.1182/blood.V114.22.1665.1665

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：664 / 665

页数：2

共 50 条

[31] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
Nobuhiko Nakamura
Senji Kasahara
Junichi Kitagawa
Hiroshi Nakamura
Michio Sawada
Kenji Fukuno
Yuhei Shibata
Yuto Kaneda
Takeshi Hara
Nobuhiro Kanemura
Hisashi Tsurumi
Masahito Shimizu
Experimental Hematology & Oncology, 11
[32] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
Nakamura, Nobuhiko
Kasahara, Senji
Kitagawa, Junichi
Nakamura, Hiroshi
Sawada, Michio
Fukuno, Kenji
Shibata, Yuhei
Kaneda, Yuto
Hara, Takeshi
Kanemura, Nobuhiro
Tsurumi, Hisashi
Shimizu, Masahito
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
[33] Marked activity of, bortezomib, rituximab, and dexamethason in relapsed and refractory mantle cell lymphoma.
Drach, Johannes
Kaufmann, Hannes
Pichelmayer, Oskar
Sagaster, Verena
Seidl, Sonja
Chott, Andreas
Zielinski, Christoph
Raderer, Markus
BLOOD, 2006, 108 (11) : 779A - 779A
[34] PHASE I/II STUDY OF ERLOTINIB AND TEMSIROLIMUS (CCI-779) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)
Wen, Patrick
Kuhn, John
Chang, Susan
Lamborn, Kathleen
Robbins, Hi
Cloughesy, Timothy
Lieberman, Frank
Mehra, Minesh
Gilbert, Mark
Cooper, Josh
Drappatz, Jan
Kesari, Santosh
Norden, Andrew
Groves, Morris
Aldape, Kenneth
Yung, W. K. Alfred
Dancey, Janet
Prados, Michael
NEURO-ONCOLOGY, 2008, 10 (05) : 824 - 824
[35] A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally recurrent endometrial cancer - NCICCTG IND 160.
Oza, AM
Elit, L
Biagi, J
Gotlieb, W
Tonkin, KS
Tsao, M
Hedley, D
Hansen, C
Dancey, J
Eisenhauer, E
Seymour, L
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9099S - 9099S
[36] Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
Galanis, E
Buckner, JC
Maurer, MJ
Kreisberg, JL
Ballman, K
Boni, J
Peralba, JM
Jenkins, RB
Dakhil, SR
Morton, RF
Jaeckle, KA
Scheithauer, BW
Dancey, J
Hidalgo, M
Walsh, DJ
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5294 - 5304
[37] Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCICIND 160.
Oza, A. M.
Elit, L.
Biagi, J.
Chapman, W.
Tsao, M.
Hedley, D.
Hansen, C.
Dancey, J.
Eisenhauer, E.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 121S - 121S
[38] Molecular inhibition of mTOR with temsirolimus (TORISEL™, CCI-779) is a promising strategy in relapsed NHL:: The University of Chicago phase II consortium.
Smith, Sonali M.
Pro, Barbara
Smith, Scott
Stiff, Patrick
Lester, Eric
Modi, Sanjiv
van Besien, Koen
BLOOD, 2006, 108 (11) : 703A - 704A
[39] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Fisher, Richard I.
Bernstein, Steven H.
Kahl, Brad S.
Djulbegovic, Benjamin
Robertson, Michael J.
de Vos, Sven
Epner, Elliot
Krishnan, Amrita
Leonard, John P.
Lonial, Sagar
Stadtmauer, Edward A.
O'Connor, Owen A.
Shi, Hongliang
Boral, Anthony L.
Goy, Andre
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4867 - 4874
[40] Clinical Efficacy and Management of Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Coiffier, Bertrand
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04): : 351 - 359

← 1 2 3 4 5 →